SCHEMBL3492011

SCHEMBL3492011

NNC(=O)c1ccnc(NCc2cccc(C(F)(F)F)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC2 Q92769 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
KDM5A P29375 1/20 0.56
KDM4C Q9H3R0 1/20 0.56
KDM5B Q9UGL1 1/20 0.56
NR3C2 P08235 1/20 0.54
AURKA O14965 2/20 0.53
RPS6KB1 P23443 2/20 0.53
AURKB Q96GD4 1/20 0.53
MLYCD O95822 1/20 0.49
MEN1 O00255 1/20 0.48
PLA2G1B P04054 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
GAA P10253 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492157 0.85 KDM5A (0.55) HDAC3HDAC1HDAC2HDAC6KDM5A
SCHEMBL31141594 0.82 HDAC3 (0.82) HDAC3HDAC1HDAC2HDAC6MLYCD
SCHEMBL3493497 0.81 GPR52 (0.57) HDAC3HDAC1HDAC2HDAC6AURKA
SCHEMBL2715062 0.79 MLYCD (0.58) NR3C2MLYCDMEN1PLA2G1BCYP1A2
SCHEMBL3494002 0.78 HDAC3 (0.54) HDAC3HDAC1HDAC2HDAC6KDM5A
SCHEMBL1767683 0.78 MAPK14 (0.60) HDAC1NR3C2AURKAMLYCDMEN1
SCHEMBL2714261 0.77 MLYCD (0.56) NR3C2MLYCDMEN1PLA2G1BCYP1A2
SCHEMBL2717072 0.76 BRAF (0.61) NR3C2AURKAMLYCDMEN1PLA2G1B
SCHEMBL2717704 0.76 SCN9A (0.57) NR3C2MLYCDMEN1PLA2G1BCYP1A2
SCHEMBL5210610 0.76 MLYCD (0.64) HDAC3HDAC1HDAC2HDAC6MLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP HDAC3 96/4885HDAC1 102/4885HDAC2 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.